| Autor: |
Xiao-Lu Zhu, Ru Feng, Qiu-Sha Huang, Mei-Ying Liang, Ming Jiang, Hui Liu, Yi Liu, Hong-Xia Yao, Lei Zhang, Shen-Xian Qian, Tong-Hua Yang, Jing-Yu Zhang, Xu-Liang Shen, Lin-Hua Yang, Jian-Da Hu, Ren-Wei Huang, Zhong-Xing Jiang, Jing-Wen Wang, Hong-Yu Zhang, Zhen Xiao, Si-Yan Zhan, Hui-Xin Liu, Xing-Lin Wang, Ying-Jun Chang, Yu Wang, Yuan Kong, Lan-Ping Xu, Kai-Yan Liu, Xiao-Hong Zhang, Cheng-Hong Yin, Yue-Ying Li, Qian-Fei Wang, Jian-Liu Wang, Xiao-Jun Huang, Xiao-Hui Zhang |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Therapeutic advances in hematology. 13 |
| ISSN: |
2040-6207 |
| Popis: |
Background: The responses of intravenous immunoglobulin (IVIg) or corticosteroids as the initial treatment on pregnancy with ITP were unsatisfactory. This study aimed to assess the safety and effectiveness of prednisone plus IVIg versus prednisone or IVIg in pregnant patients with immune thrombocytopenia (ITP). Methods: Between 1 January 2010 and 31 December 2020, 970 pregnancies diagnosed with ITP at 19 collaborative centers in China were reviewed in this observational study. A total of 513 pregnancies (52.89%) received no intervention. Concerning the remaining pregnancies, 151 (33.04%) pregnancies received an initial treatment of prednisone plus IVIg, 105 (22.98%) pregnancies received IVIg alone, and 172 (37.64%) pregnancies only received prednisone. Results: Regarding the maternal response to the initial treatment, no differences were found among the three treatment groups (41.1% for prednisone plus IVIg, 33.1% for prednisone, and 38.1% for IVIg). However, a significant difference was observed in the time to response between the prednisone plus IVIg group (4.39 ± 2.54 days) and prednisone group (7.29 ± 5.01 days; p Conclusion: These findings suggest that prednisone plus IVIg may represent a potential combination therapy for pregnant patients with ITP. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
